ERM has acted for Gilde Healthcare, a Dutch-based healthcare investor that has a portfolio of investments across Europe, on their $20 million investment in Nyxoah S.A., a medical device company focused on developing a neuro-stimulation based therapy for patients suffering from Obstructive Sleep Apnea (OSA).
The proceeds will be used to finance Nyxoah’s go-to-market strategy, including the BLAST OSA international study, CE Mark approval and the US FDA approval process.
For media coverage of the investment, please click here.
High-Tech and Start-ups practice
Epstein Rosenblum Maoz (ERM)’s high-tech and start-ups practice regularly provides legal advice to leading Israeli and international clients from pre-incorporation through to exit, as well as on the most complex transactions carried out in Israel and abroad.